Natco Pharma Limited — PPTs, 12-11-2024: Investor Presentation

**Financial Highlights:** NATCO Pharma reported total revenue of INR 14,349 mn for Q2 FY25, an increase from INR 10,608 mn in Q2 FY24. Pharma exports contributed INR 12,113 mn, while domestic formulations generated INR 1,023 mn. The EBITDA stood at INR 8,681 mn with a robust margin of 60.5%. Net profit rose to INR 6,765 mn, translating to a basic and diluted EPS of INR 37.81.

**Strategic Initiatives and Growth Drivers:** The company continues to innovate with a strong focus on their product pipeline, including 30 Para IVs, of which 14 are approved. Recently, NATCO invested USD 8 mn in eGenesis, a company developing human-compatible organs.

**Business Developments:** The Board declared a second interim dividend of INR 1.50 per equity share.

**Market Position and Competitive Advantage:** NATCO's extensive product pipeline and solid export performance underscore its competitive positioning in the market, especially in oncology and chronic disease treatments.

**Investor Implications:** With steady revenue growth and a strong operational outlook, NATCO Pharma presents potential for continued profitability and investor interest as it expands its pipeline and explores novel therapeutics.